Has Surinder Saini, MD received payments from drug or device companies?

Yes. Drug and device makers reported $593 in general payments to Surinder Saini, MD across 14 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Surinder Saini, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Surinder Saini, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Surinder Saini, MD

Gastroenterology · Newport Beach, CANPI 1750304671

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 96.5% of the total across 14 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 7 manufacturers reported payments, led by AbbVie at 29.6% of the total. Reporting peaked in 2019 at $208 and has fallen 81.6% since, to $38 in 2025. That places this record below the midpoint for gastroenterology clinicians in CA, where the typical reported total is $1,790.

$593in general payments, 2019–2025

Across 14 payments — averaging $42.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AbbVie$175
Endogastric Solutions, Inc$125
Apollo Endosurgery US Inc$111
Covidien LP$100
Sanofi$38
Boston Scientific$25
plus $18 from 1 others

$65,006in research payments, 2019–2025

Across 27 payments — averaging $2407.62 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Pfizer$51K
AbbVie$13K
Intercept Pharmaceuticals, Inc.$1K
Alnylam Pharmaceuticals Inc.$182

What the payments were for

Travel & lodging$214%
Food & beverage$57296%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AbbVie(2 entities)	5	$175
Endogastric Solutions, Inc	3	$125
Apollo Endosurgery US Inc	1	$111
Covidien LP	2	$100
Sanofi	1	$38
Boston Scientific	1	$25
GSK	1	$18

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

OverStitch Endoscopic Suturing System$111
Mavyret$104

How this compares

$593 in reported general payments places this provider in the 30th percentile of 1,885 gastroenterology providers in California.

See all gastroenterology providers in California →

Medicare billing

Part B allowed, 2024

$216,205

Medicare patients

609

Services billed

1,763

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
ZenpepLipase/Protease/Amylase	22	$104,874
Mesalamine	48	$40,558
ClenpiqSod Picosulf/Mag Ox/Citric Ac	66	$11,276
Dexlansoprazole DrDexlansoprazole	22	$5,431
Lactulose	187	$4,783
Colestipol Hcl	52	$4,774
Sucralfate	82	$3,187
Pantoprazole Sodium	217	$2,291
Lubiprostone	13	$1,300
Famotidine	112	$1,218
Amitriptyline Hcl	54	$1,100
Dicyclomine Hcl	64	$1,082
Misoprostol	13	$1,036
ConstuloseLactulose	42	$863
EnuloseLactulose	21	$625

Paid to pharmacies, not to this prescriber.

Other gastroenterology in Newport Beach

Kenneth ChangNewport Beach$1.3M
Jennifer PhanNewport Beach$226K
Bennett RothLos Angeles$2.8M
Douglas NguyenMission Viejo$2M
Sammy SaabLos Angeles$1.9M
Joo HwangStanford$1M
Drew SchembreWalnut Creek$659K
Quan Nhula Jolla$641K
Sadeea AbbasiLos Angeles$556K
Ali RezaieWest Hollywood$519K

See the full list for California →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →